- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Targeting TNFR2 for cancer immunotherapy: recent advances and future directions ; volume:22 ; number:1 ; day:2 ; month:9 ; year:2024 ; pages:1-19 ; date:12.2024
Journal of translational medicine ; 22, Heft 1 (2.9.2024), 1-19, 12.2024
- Creator
-
Li, Linxue
Ye, Ruiwei
Li, Yingying
Pan, Hanyu
Han, Sheng
Lu, Yiming
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12967-024-05620-x
- URN
-
urn:nbn:de:101:1-2411172345097.139018779907
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.22500, 7:51 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Li, Linxue
- Ye, Ruiwei
- Li, Yingying
- Pan, Hanyu
- Han, Sheng
- Lu, Yiming
- SpringerLink (Online service)
Other Objects (12)
Targeting TIGIT for cancer immunotherapy: recent advances and future directions
Targeting lymph node delivery with nanovaccines for cancer immunotherapy: recent advances and future directions
Targeting CD24/Siglec-10 signal pathway for cancer immunotherapy: recent advances and future directions
Targeting macrophages in hematological malignancies: recent advances and future directions
Recent advances in cancer immunotherapy
Recent advances in cancer immunotherapy
Recent advances in cancer immunotherapy
Targeting toll-like receptor 7/8 for immunotherapy: recent advances and prospectives
Mesoporous Silica Nanoparticles as an Ideal Platform for Cancer Immunotherapy: Recent Advances and Future Directions.
Correction: Targeting toll-like receptor 7/8 for immunotherapy: recent advances and prospectives
Emerging immunological strategies: recent advances and future directions
Recent advances of human tumor immunology and immunotherapy
Targeting TIGIT for cancer immunotherapy: recent advances and future directions
Targeting lymph node delivery with nanovaccines for cancer immunotherapy: recent advances and future directions
Targeting CD24/Siglec-10 signal pathway for cancer immunotherapy: recent advances and future directions
Targeting macrophages in hematological malignancies: recent advances and future directions
Recent advances in cancer immunotherapy
Recent advances in cancer immunotherapy
Recent advances in cancer immunotherapy
Targeting toll-like receptor 7/8 for immunotherapy: recent advances and prospectives
Mesoporous Silica Nanoparticles as an Ideal Platform for Cancer Immunotherapy: Recent Advances and Future Directions.
Correction: Targeting toll-like receptor 7/8 for immunotherapy: recent advances and prospectives
Emerging immunological strategies: recent advances and future directions
Recent advances of human tumor immunology and immunotherapy
Targeting TIGIT for cancer immunotherapy: recent advances and future directions
Targeting lymph node delivery with nanovaccines for cancer immunotherapy: recent advances and future directions
Targeting CD24/Siglec-10 signal pathway for cancer immunotherapy: recent advances and future directions
Targeting macrophages in hematological malignancies: recent advances and future directions
Recent advances in cancer immunotherapy
Recent advances in cancer immunotherapy
Recent advances in cancer immunotherapy
Targeting toll-like receptor 7/8 for immunotherapy: recent advances and prospectives
Mesoporous Silica Nanoparticles as an Ideal Platform for Cancer Immunotherapy: Recent Advances and Future Directions.
Correction: Targeting toll-like receptor 7/8 for immunotherapy: recent advances and prospectives
Emerging immunological strategies: recent advances and future directions